nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—FOLR1—ovarian cancer	0.226	0.784	CbGaD
Methotrexate—colon cancer—ovarian cancer	0.108	0.3	CtDrD
Methotrexate—breast cancer—ovarian cancer	0.102	0.283	CtDrD
Methotrexate—testicular cancer—ovarian cancer	0.0767	0.213	CtDrD
Methotrexate—germ cell cancer—ovarian cancer	0.0735	0.204	CtDrD
Methotrexate—TYMS—ovarian cancer	0.0498	0.172	CbGaD
Methotrexate—SLCO1A2—Chlorambucil—ovarian cancer	0.0233	0.112	CbGbCtD
Methotrexate—ABCC10—Paclitaxel—ovarian cancer	0.0232	0.111	CbGbCtD
Methotrexate—ABCC10—Docetaxel—ovarian cancer	0.0168	0.0805	CbGbCtD
Methotrexate—SLCO1B3—Paclitaxel—ovarian cancer	0.0129	0.0621	CbGbCtD
Methotrexate—ABCB1—ovarian cancer	0.0126	0.0437	CbGaD
Methotrexate—ABCC10—Doxorubicin—ovarian cancer	0.0125	0.06	CbGbCtD
Methotrexate—ABCG2—Topotecan—ovarian cancer	0.0121	0.0581	CbGbCtD
Methotrexate—SLCO1B3—Docetaxel—ovarian cancer	0.00936	0.0449	CbGbCtD
Methotrexate—ABCC1—Epirubicin—ovarian cancer	0.00907	0.0436	CbGbCtD
Methotrexate—ABCC1—Paclitaxel—ovarian cancer	0.00895	0.043	CbGbCtD
Methotrexate—SLC22A7—Docetaxel—ovarian cancer	0.00824	0.0396	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—ovarian cancer	0.00785	0.0377	CbGbCtD
Methotrexate—ABCC2—Paclitaxel—ovarian cancer	0.00662	0.0318	CbGbCtD
Methotrexate—ABCC1—Docetaxel—ovarian cancer	0.00647	0.0311	CbGbCtD
Methotrexate—ABCC2—Carboplatin—ovarian cancer	0.00623	0.0299	CbGbCtD
Methotrexate—ABCG2—Paclitaxel—ovarian cancer	0.00599	0.0288	CbGbCtD
Methotrexate—ABCG2—Carboplatin—ovarian cancer	0.00564	0.0271	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—ovarian cancer	0.00482	0.0232	CbGbCtD
Methotrexate—ABCC2—Docetaxel—ovarian cancer	0.00479	0.023	CbGbCtD
Methotrexate—ABCB1—Topotecan—ovarian cancer	0.00436	0.0209	CbGbCtD
Methotrexate—ABCG2—Docetaxel—ovarian cancer	0.00433	0.0208	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—ovarian cancer	0.00357	0.0171	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—ovarian cancer	0.00323	0.0155	CbGbCtD
Methotrexate—ABCB1—Vinorelbine—ovarian cancer	0.00307	0.0148	CbGbCtD
Methotrexate—FOLR1—oviduct—ovarian cancer	0.00234	0.0624	CbGeAlD
Methotrexate—ABCB1—Paclitaxel—ovarian cancer	0.00216	0.0104	CbGbCtD
Methotrexate—ABCB1—Docetaxel—ovarian cancer	0.00156	0.0075	CbGbCtD
Methotrexate—ABCB1—Doxorubicin—ovarian cancer	0.00116	0.00559	CbGbCtD
Methotrexate—ABCC11—embryo—ovarian cancer	0.000692	0.0184	CbGeAlD
Methotrexate—Raltitrexed—TYMS—ovarian cancer	0.000592	0.32	CrCbGaD
Methotrexate—FOLR1—epithelium—ovarian cancer	0.000589	0.0157	CbGeAlD
Methotrexate—FOLR1—uterine cervix—ovarian cancer	0.000584	0.0155	CbGeAlD
Methotrexate—FOLR1—decidua—ovarian cancer	0.000556	0.0148	CbGeAlD
Methotrexate—FOLR1—endometrium—ovarian cancer	0.000528	0.0141	CbGeAlD
Methotrexate—GGH—myometrium—ovarian cancer	0.000498	0.0133	CbGeAlD
Methotrexate—FOLR1—uterus—ovarian cancer	0.000487	0.013	CbGeAlD
Methotrexate—TYMS—Docetaxel—Paclitaxel—ovarian cancer	0.000486	0.472	CbGdCrCtD
Methotrexate—ABCC11—gonad—ovarian cancer	0.000469	0.0125	CbGeAlD
Methotrexate—Pralatrexate—TYMS—ovarian cancer	0.000448	0.243	CrCbGaD
Methotrexate—Leucovorin—TYMS—ovarian cancer	0.000448	0.243	CrCbGaD
Methotrexate—FPGS—myometrium—ovarian cancer	0.000438	0.0117	CbGeAlD
Methotrexate—FOLR1—female reproductive system—ovarian cancer	0.000437	0.0116	CbGeAlD
Methotrexate—SLC19A1—gonad—ovarian cancer	0.000429	0.0114	CbGeAlD
Methotrexate—ABCC11—female reproductive system—ovarian cancer	0.000419	0.0112	CbGeAlD
Methotrexate—ATIC—embryo—ovarian cancer	0.000408	0.0109	CbGeAlD
Methotrexate—FOLR1—female gonad—ovarian cancer	0.000398	0.0106	CbGeAlD
Methotrexate—GGH—uterine cervix—ovarian cancer	0.000388	0.0103	CbGeAlD
Methotrexate—SLC19A1—female reproductive system—ovarian cancer	0.000383	0.0102	CbGeAlD
Methotrexate—ABCC11—female gonad—ovarian cancer	0.000382	0.0102	CbGeAlD
Methotrexate—SLC46A1—decidua—ovarian cancer	0.000376	0.01	CbGeAlD
Methotrexate—GGH—decidua—ovarian cancer	0.00037	0.00984	CbGeAlD
Methotrexate—Pemetrexed—TYMS—ovarian cancer	0.000358	0.194	CrCbGaD
Methotrexate—GGH—endometrium—ovarian cancer	0.000351	0.00934	CbGeAlD
Methotrexate—ABCC11—testis—ovarian cancer	0.000338	0.00901	CbGeAlD
Methotrexate—ATIC—epithelium—ovarian cancer	0.000333	0.00886	CbGeAlD
Methotrexate—GGH—gonad—ovarian cancer	0.000325	0.00866	CbGeAlD
Methotrexate—FPGS—decidua—ovarian cancer	0.000325	0.00865	CbGeAlD
Methotrexate—GGH—uterus—ovarian cancer	0.000323	0.00861	CbGeAlD
Methotrexate—SLCO4C1—endometrium—ovarian cancer	0.000311	0.00829	CbGeAlD
Methotrexate—SLCO3A1—myometrium—ovarian cancer	0.00031	0.00825	CbGeAlD
Methotrexate—SLC19A1—testis—ovarian cancer	0.000309	0.00824	CbGeAlD
Methotrexate—FPGS—endometrium—ovarian cancer	0.000308	0.00821	CbGeAlD
Methotrexate—GGH—female reproductive system—ovarian cancer	0.000291	0.00774	CbGeAlD
Methotrexate—DHFR—myometrium—ovarian cancer	0.000285	0.00758	CbGeAlD
Methotrexate—ATIC—gonad—ovarian cancer	0.000277	0.00737	CbGeAlD
Methotrexate—ATIC—uterus—ovarian cancer	0.000275	0.00732	CbGeAlD
Methotrexate—GGH—bone marrow—ovarian cancer	0.000274	0.00731	CbGeAlD
Methotrexate—DHFR—embryo—ovarian cancer	0.000274	0.00729	CbGeAlD
Methotrexate—PGD—myometrium—ovarian cancer	0.000274	0.00729	CbGeAlD
Methotrexate—SLC46A1—female gonad—ovarian cancer	0.000269	0.00716	CbGeAlD
Methotrexate—GGH—female gonad—ovarian cancer	0.000264	0.00704	CbGeAlD
Methotrexate—GGH—vagina—ovarian cancer	0.000263	0.007	CbGeAlD
Methotrexate—FPGS—female reproductive system—ovarian cancer	0.000256	0.0068	CbGeAlD
Methotrexate—ATIC—female reproductive system—ovarian cancer	0.000247	0.00658	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—ovarian cancer	0.000243	0.00648	CbGeAlD
Methotrexate—TYMS—Paclitaxel—Docetaxel—ovarian cancer	0.000243	0.236	CbGdCrCtD
Methotrexate—SLCO3A1—uterine cervix—ovarian cancer	0.000241	0.00642	CbGeAlD
Methotrexate—AOX1—myometrium—ovarian cancer	0.000241	0.00642	CbGeAlD
Methotrexate—SLC46A1—testis—ovarian cancer	0.000238	0.00635	CbGeAlD
Methotrexate—ABCC10—myometrium—ovarian cancer	0.000235	0.00625	CbGeAlD
Methotrexate—GGH—testis—ovarian cancer	0.000235	0.00625	CbGeAlD
Methotrexate—SLCO4C1—vagina—ovarian cancer	0.000233	0.00621	CbGeAlD
Methotrexate—FPGS—female gonad—ovarian cancer	0.000232	0.00619	CbGeAlD
Methotrexate—FPGS—vagina—ovarian cancer	0.000231	0.00615	CbGeAlD
Methotrexate—SLCO1B3—vagina—ovarian cancer	0.000227	0.00603	CbGeAlD
Methotrexate—ATIC—female gonad—ovarian cancer	0.000225	0.00599	CbGeAlD
Methotrexate—SLC19A1—lymph node—ovarian cancer	0.000224	0.00597	CbGeAlD
Methotrexate—TYMS—uterine cervix—ovarian cancer	0.000224	0.00596	CbGeAlD
Methotrexate—DHFR—uterine cervix—ovarian cancer	0.000221	0.0059	CbGeAlD
Methotrexate—PGD—uterine cervix—ovarian cancer	0.000213	0.00567	CbGeAlD
Methotrexate—DHFR—decidua—ovarian cancer	0.000211	0.00562	CbGeAlD
Methotrexate—FPGS—testis—ovarian cancer	0.000206	0.00549	CbGeAlD
Methotrexate—PGD—decidua—ovarian cancer	0.000203	0.0054	CbGeAlD
Methotrexate—SLCO3A1—gonad—ovarian cancer	0.000202	0.00539	CbGeAlD
Methotrexate—TYMS—endometrium—ovarian cancer	0.000202	0.00539	CbGeAlD
Methotrexate—SLC16A1—epithelium—ovarian cancer	0.0002	0.00534	CbGeAlD
Methotrexate—DHFR—endometrium—ovarian cancer	0.0002	0.00533	CbGeAlD
Methotrexate—SLC22A11—female reproductive system—ovarian cancer	0.0002	0.00531	CbGeAlD
Methotrexate—ATIC—testis—ovarian cancer	0.000199	0.00531	CbGeAlD
Methotrexate—PGD—endometrium—ovarian cancer	0.000193	0.00513	CbGeAlD
Methotrexate—SLC16A1—decidua—ovarian cancer	0.000189	0.00504	CbGeAlD
Methotrexate—TYMS—gonad—ovarian cancer	0.000188	0.005	CbGeAlD
Methotrexate—AOX1—uterine cervix—ovarian cancer	0.000188	0.00499	CbGeAlD
Methotrexate—DHFR—gonad—ovarian cancer	0.000186	0.00495	CbGeAlD
Methotrexate—DHFR—uterus—ovarian cancer	0.000185	0.00491	CbGeAlD
Methotrexate—MTHFR—female reproductive system—ovarian cancer	0.000184	0.00489	CbGeAlD
Methotrexate—ABCC10—uterine cervix—ovarian cancer	0.000183	0.00486	CbGeAlD
Methotrexate—SLCO3A1—female reproductive system—ovarian cancer	0.000181	0.00481	CbGeAlD
Methotrexate—SLC16A1—endometrium—ovarian cancer	0.00018	0.00479	CbGeAlD
Methotrexate—AOX1—decidua—ovarian cancer	0.000179	0.00476	CbGeAlD
Methotrexate—PGD—gonad—ovarian cancer	0.000179	0.00476	CbGeAlD
Methotrexate—PGD—uterus—ovarian cancer	0.000177	0.00473	CbGeAlD
Methotrexate—ABCC3—decidua—ovarian cancer	0.000175	0.00465	CbGeAlD
Methotrexate—ABCC10—decidua—ovarian cancer	0.000174	0.00463	CbGeAlD
Methotrexate—SLC46A1—lymph node—ovarian cancer	0.000173	0.0046	CbGeAlD
Methotrexate—GGH—lymph node—ovarian cancer	0.00017	0.00453	CbGeAlD
Methotrexate—AOX1—endometrium—ovarian cancer	0.00017	0.00452	CbGeAlD
Methotrexate—TYMS—female reproductive system—ovarian cancer	0.000168	0.00446	CbGeAlD
Methotrexate—MTHFR—female gonad—ovarian cancer	0.000167	0.00445	CbGeAlD
Methotrexate—TYMS—Vincristine—Vinorelbine—ovarian cancer	0.000167	0.162	CbGdCrCtD
Methotrexate—SLC16A1—gonad—ovarian cancer	0.000167	0.00444	CbGeAlD
Methotrexate—ABCC1—myometrium—ovarian cancer	0.000166	0.00442	CbGeAlD
Methotrexate—DHFR—female reproductive system—ovarian cancer	0.000166	0.00442	CbGeAlD
Methotrexate—SLCO1C1—testis—ovarian cancer	0.000166	0.00441	CbGeAlD
Methotrexate—SLC16A1—uterus—ovarian cancer	0.000166	0.00441	CbGeAlD
Methotrexate—ABCC10—endometrium—ovarian cancer	0.000165	0.0044	CbGeAlD
Methotrexate—SLCO3A1—female gonad—ovarian cancer	0.000164	0.00438	CbGeAlD
Methotrexate—SLCO3A1—vagina—ovarian cancer	0.000163	0.00435	CbGeAlD
Methotrexate—PGD—female reproductive system—ovarian cancer	0.00016	0.00425	CbGeAlD
Methotrexate—TYMS—bone marrow—ovarian cancer	0.000158	0.00421	CbGeAlD
Methotrexate—AOX1—gonad—ovarian cancer	0.000157	0.00419	CbGeAlD
Methotrexate—SLC22A7—testis—ovarian cancer	0.000157	0.00419	CbGeAlD
Methotrexate—DHFR—bone marrow—ovarian cancer	0.000157	0.00417	CbGeAlD
Methotrexate—AOX1—uterus—ovarian cancer	0.000156	0.00416	CbGeAlD
Methotrexate—ABCC10—gonad—ovarian cancer	0.000153	0.00408	CbGeAlD
Methotrexate—TYMS—female gonad—ovarian cancer	0.000153	0.00406	CbGeAlD
Methotrexate—ABCC10—uterus—ovarian cancer	0.000152	0.00405	CbGeAlD
Methotrexate—TYMS—vagina—ovarian cancer	0.000152	0.00404	CbGeAlD
Methotrexate—DHFR—female gonad—ovarian cancer	0.000151	0.00402	CbGeAlD
Methotrexate—PGD—bone marrow—ovarian cancer	0.000151	0.00401	CbGeAlD
Methotrexate—DHFR—vagina—ovarian cancer	0.00015	0.004	CbGeAlD
Methotrexate—FPGS—lymph node—ovarian cancer	0.000149	0.00398	CbGeAlD
Methotrexate—SLC16A1—female reproductive system—ovarian cancer	0.000149	0.00397	CbGeAlD
Methotrexate—MTHFR—testis—ovarian cancer	0.000148	0.00395	CbGeAlD
Methotrexate—SLCO3A1—testis—ovarian cancer	0.000146	0.00388	CbGeAlD
Methotrexate—PGD—female gonad—ovarian cancer	0.000145	0.00387	CbGeAlD
Methotrexate—SLCO1B1—female reproductive system—ovarian cancer	0.000145	0.00386	CbGeAlD
Methotrexate—ATIC—lymph node—ovarian cancer	0.000145	0.00385	CbGeAlD
Methotrexate—PGD—vagina—ovarian cancer	0.000144	0.00384	CbGeAlD
Methotrexate—AOX1—female reproductive system—ovarian cancer	0.000141	0.00374	CbGeAlD
Methotrexate—ABCC3—female reproductive system—ovarian cancer	0.000137	0.00366	CbGeAlD
Methotrexate—ABCG2—myometrium—ovarian cancer	0.000137	0.00366	CbGeAlD
Methotrexate—ABCC10—female reproductive system—ovarian cancer	0.000137	0.00364	CbGeAlD
Methotrexate—SLC16A1—female gonad—ovarian cancer	0.000136	0.00361	CbGeAlD
Methotrexate—TYMS—testis—ovarian cancer	0.000135	0.0036	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vinorelbine—ovarian cancer	0.000134	0.13	CbGdCrCtD
Methotrexate—DHFR—testis—ovarian cancer	0.000134	0.00357	CbGeAlD
Methotrexate—ABCC10—bone marrow—ovarian cancer	0.000129	0.00344	CbGeAlD
Methotrexate—ABCC1—uterine cervix—ovarian cancer	0.000129	0.00344	CbGeAlD
Methotrexate—PGD—testis—ovarian cancer	0.000129	0.00343	CbGeAlD
Methotrexate—AOX1—female gonad—ovarian cancer	0.000128	0.00341	CbGeAlD
Methotrexate—AOX1—vagina—ovarian cancer	0.000127	0.00338	CbGeAlD
Methotrexate—ABCC4—uterus—ovarian cancer	0.000126	0.00336	CbGeAlD
Methotrexate—ABCC3—female gonad—ovarian cancer	0.000125	0.00333	CbGeAlD
Methotrexate—ABCC10—female gonad—ovarian cancer	0.000124	0.00331	CbGeAlD
Methotrexate—ABCC10—vagina—ovarian cancer	0.000124	0.00329	CbGeAlD
Methotrexate—ABCC1—decidua—ovarian cancer	0.000123	0.00328	CbGeAlD
Methotrexate—SLC16A1—testis—ovarian cancer	0.00012	0.0032	CbGeAlD
Methotrexate—SLCO1C1—lymph node—ovarian cancer	0.00012	0.0032	CbGeAlD
Methotrexate—ABCC1—endometrium—ovarian cancer	0.000117	0.00311	CbGeAlD
Methotrexate—ABCC4—female reproductive system—ovarian cancer	0.000113	0.00302	CbGeAlD
Methotrexate—AOX1—testis—ovarian cancer	0.000113	0.00302	CbGeAlD
Methotrexate—ABCC3—testis—ovarian cancer	0.000111	0.00295	CbGeAlD
Methotrexate—ABCC10—testis—ovarian cancer	0.00011	0.00294	CbGeAlD
Methotrexate—ABCC2—female reproductive system—ovarian cancer	0.00011	0.00292	CbGeAlD
Methotrexate—ABCC1—uterus—ovarian cancer	0.000108	0.00287	CbGeAlD
Methotrexate—MTHFR—lymph node—ovarian cancer	0.000107	0.00286	CbGeAlD
Methotrexate—ABCC4—bone marrow—ovarian cancer	0.000107	0.00285	CbGeAlD
Methotrexate—ABCG2—uterine cervix—ovarian cancer	0.000107	0.00285	CbGeAlD
Methotrexate—SLCO3A1—lymph node—ovarian cancer	0.000106	0.00281	CbGeAlD
Methotrexate—ABCC4—female gonad—ovarian cancer	0.000103	0.00275	CbGeAlD
Methotrexate—ABCG2—decidua—ovarian cancer	0.000102	0.00271	CbGeAlD
Methotrexate—TYMS—lymph node—ovarian cancer	9.8e-05	0.00261	CbGeAlD
Methotrexate—DHFR—lymph node—ovarian cancer	9.71e-05	0.00258	CbGeAlD
Methotrexate—ABCG2—endometrium—ovarian cancer	9.67e-05	0.00257	CbGeAlD
Methotrexate—SLCO1A2—testis—ovarian cancer	9.52e-05	0.00253	CbGeAlD
Methotrexate—ALB—testis—ovarian cancer	9.46e-05	0.00252	CbGeAlD
Methotrexate—PGD—lymph node—ovarian cancer	9.33e-05	0.00248	CbGeAlD
Methotrexate—ABCC4—testis—ovarian cancer	9.16e-05	0.00244	CbGeAlD
Methotrexate—ABCG2—uterus—ovarian cancer	8.91e-05	0.00237	CbGeAlD
Methotrexate—ABCC2—testis—ovarian cancer	8.86e-05	0.00236	CbGeAlD
Methotrexate—ABCC1—female gonad—ovarian cancer	8.8e-05	0.00234	CbGeAlD
Methotrexate—ABCC1—vagina—ovarian cancer	8.75e-05	0.00233	CbGeAlD
Methotrexate—SLC16A1—lymph node—ovarian cancer	8.71e-05	0.00232	CbGeAlD
Methotrexate—AOX1—lymph node—ovarian cancer	8.22e-05	0.00219	CbGeAlD
Methotrexate—ABCC3—lymph node—ovarian cancer	8.04e-05	0.00214	CbGeAlD
Methotrexate—ABCC10—lymph node—ovarian cancer	8e-05	0.00213	CbGeAlD
Methotrexate—ABCC1—testis—ovarian cancer	7.81e-05	0.00208	CbGeAlD
Methotrexate—ABCG2—bone marrow—ovarian cancer	7.56e-05	0.00201	CbGeAlD
Methotrexate—ABCG2—female gonad—ovarian cancer	7.29e-05	0.00194	CbGeAlD
Methotrexate—ABCG2—vagina—ovarian cancer	7.24e-05	0.00193	CbGeAlD
Methotrexate—ALB—lymph node—ovarian cancer	6.86e-05	0.00183	CbGeAlD
Methotrexate—ABCB1—myometrium—ovarian cancer	6.77e-05	0.0018	CbGeAlD
Methotrexate—ABCC4—lymph node—ovarian cancer	6.64e-05	0.00177	CbGeAlD
Methotrexate—ABCB1—embryo—ovarian cancer	6.52e-05	0.00173	CbGeAlD
Methotrexate—ABCG2—testis—ovarian cancer	6.46e-05	0.00172	CbGeAlD
Methotrexate—ABCC2—lymph node—ovarian cancer	6.43e-05	0.00171	CbGeAlD
Methotrexate—ABCC1—lymph node—ovarian cancer	5.66e-05	0.00151	CbGeAlD
Methotrexate—ABCB1—epithelium—ovarian cancer	5.32e-05	0.00142	CbGeAlD
Methotrexate—ABCB1—uterine cervix—ovarian cancer	5.27e-05	0.0014	CbGeAlD
Methotrexate—ABCB1—decidua—ovarian cancer	5.02e-05	0.00134	CbGeAlD
Methotrexate—ABCB1—endometrium—ovarian cancer	4.77e-05	0.00127	CbGeAlD
Methotrexate—ABCG2—lymph node—ovarian cancer	4.69e-05	0.00125	CbGeAlD
Methotrexate—ABCB1—gonad—ovarian cancer	4.42e-05	0.00118	CbGeAlD
Methotrexate—ABCB1—uterus—ovarian cancer	4.39e-05	0.00117	CbGeAlD
Methotrexate—ABCB1—female reproductive system—ovarian cancer	3.95e-05	0.00105	CbGeAlD
Methotrexate—ABCB1—bone marrow—ovarian cancer	3.73e-05	0.000993	CbGeAlD
Methotrexate—ABCB1—female gonad—ovarian cancer	3.59e-05	0.000957	CbGeAlD
Methotrexate—ABCB1—vagina—ovarian cancer	3.57e-05	0.000951	CbGeAlD
Methotrexate—ABCB1—testis—ovarian cancer	3.19e-05	0.000849	CbGeAlD
Methotrexate—Skin disorder—Paclitaxel—ovarian cancer	2.64e-05	0.000375	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	2.63e-05	0.000374	CcSEcCtD
Methotrexate—Hyperhidrosis—Paclitaxel—ovarian cancer	2.63e-05	0.000373	CcSEcCtD
Methotrexate—Anaemia—Docetaxel—ovarian cancer	2.61e-05	0.000371	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—ovarian cancer	2.6e-05	0.000369	CcSEcCtD
Methotrexate—Anorexia—Paclitaxel—ovarian cancer	2.59e-05	0.000368	CcSEcCtD
Methotrexate—Vomiting—Vinorelbine—ovarian cancer	2.57e-05	0.000365	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—ovarian cancer	2.56e-05	0.000363	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—ovarian cancer	2.56e-05	0.000363	CcSEcCtD
Methotrexate—Rash—Vinorelbine—ovarian cancer	2.55e-05	0.000362	CcSEcCtD
Methotrexate—Dermatitis—Vinorelbine—ovarian cancer	2.55e-05	0.000362	CcSEcCtD
Methotrexate—Hypotension—Paclitaxel—ovarian cancer	2.54e-05	0.000361	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—ovarian cancer	2.54e-05	0.000361	CcSEcCtD
Methotrexate—Headache—Vinorelbine—ovarian cancer	2.53e-05	0.00036	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—ovarian cancer	2.53e-05	0.000359	CcSEcCtD
Methotrexate—Leukopenia—Docetaxel—ovarian cancer	2.53e-05	0.000359	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—ovarian cancer	2.5e-05	0.000356	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—ovarian cancer	2.49e-05	0.000354	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—ovarian cancer	2.48e-05	0.000352	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	2.48e-05	0.000352	CcSEcCtD
Methotrexate—Cough—Docetaxel—ovarian cancer	2.46e-05	0.00035	CcSEcCtD
Methotrexate—Insomnia—Paclitaxel—ovarian cancer	2.46e-05	0.000349	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—ovarian cancer	2.45e-05	0.000348	CcSEcCtD
Methotrexate—Convulsion—Docetaxel—ovarian cancer	2.45e-05	0.000348	CcSEcCtD
Methotrexate—Paraesthesia—Paclitaxel—ovarian cancer	2.44e-05	0.000347	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—ovarian cancer	2.44e-05	0.000346	CcSEcCtD
Methotrexate—Infestation—Epirubicin—ovarian cancer	2.44e-05	0.000346	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—ovarian cancer	2.44e-05	0.000346	CcSEcCtD
Methotrexate—Dyspnoea—Paclitaxel—ovarian cancer	2.42e-05	0.000344	CcSEcCtD
Methotrexate—Somnolence—Paclitaxel—ovarian cancer	2.42e-05	0.000343	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	2.42e-05	0.000343	CcSEcCtD
Methotrexate—Chest pain—Docetaxel—ovarian cancer	2.4e-05	0.000341	CcSEcCtD
Methotrexate—Myalgia—Docetaxel—ovarian cancer	2.4e-05	0.000341	CcSEcCtD
Methotrexate—Arthralgia—Docetaxel—ovarian cancer	2.4e-05	0.000341	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—ovarian cancer	2.4e-05	0.000341	CcSEcCtD
Methotrexate—Nausea—Vinorelbine—ovarian cancer	2.4e-05	0.000341	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—ovarian cancer	2.4e-05	0.00034	CcSEcCtD
Methotrexate—Dyspepsia—Paclitaxel—ovarian cancer	2.39e-05	0.00034	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	2.39e-05	0.000339	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—ovarian cancer	2.37e-05	0.000337	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—ovarian cancer	2.37e-05	0.000337	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—ovarian cancer	2.36e-05	0.000336	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—ovarian cancer	2.36e-05	0.000336	CcSEcCtD
Methotrexate—Decreased appetite—Paclitaxel—ovarian cancer	2.36e-05	0.000336	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	2.35e-05	0.000334	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Paclitaxel—ovarian cancer	2.35e-05	0.000333	CcSEcCtD
Methotrexate—Fatigue—Paclitaxel—ovarian cancer	2.34e-05	0.000333	CcSEcCtD
Methotrexate—Sweating—Epirubicin—ovarian cancer	2.34e-05	0.000332	CcSEcCtD
Methotrexate—Pain—Paclitaxel—ovarian cancer	2.32e-05	0.00033	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—ovarian cancer	2.32e-05	0.00033	CcSEcCtD
Methotrexate—Confusional state—Docetaxel—ovarian cancer	2.32e-05	0.00033	CcSEcCtD
Methotrexate—ABCB1—lymph node—ovarian cancer	2.31e-05	0.000615	CbGeAlD
Methotrexate—Photosensitivity reaction—Doxorubicin—ovarian cancer	2.31e-05	0.000328	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—ovarian cancer	2.3e-05	0.000327	CcSEcCtD
Methotrexate—Anaphylactic shock—Docetaxel—ovarian cancer	2.3e-05	0.000327	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—ovarian cancer	2.3e-05	0.000327	CcSEcCtD
Methotrexate—Infection—Docetaxel—ovarian cancer	2.29e-05	0.000325	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—ovarian cancer	2.27e-05	0.000323	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—ovarian cancer	2.27e-05	0.000322	CcSEcCtD
Methotrexate—Nervous system disorder—Docetaxel—ovarian cancer	2.26e-05	0.000321	CcSEcCtD
Methotrexate—Thrombocytopenia—Docetaxel—ovarian cancer	2.26e-05	0.000321	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—ovarian cancer	2.25e-05	0.00032	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—ovarian cancer	2.25e-05	0.00032	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—ovarian cancer	2.25e-05	0.00032	CcSEcCtD
Methotrexate—Feeling abnormal—Paclitaxel—ovarian cancer	2.24e-05	0.000318	CcSEcCtD
Methotrexate—Skin disorder—Docetaxel—ovarian cancer	2.24e-05	0.000318	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	2.24e-05	0.000318	CcSEcCtD
Methotrexate—Gastrointestinal pain—Paclitaxel—ovarian cancer	2.22e-05	0.000316	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—ovarian cancer	2.22e-05	0.000315	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—ovarian cancer	2.2e-05	0.000312	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—ovarian cancer	2.2e-05	0.000312	CcSEcCtD
Methotrexate—Anorexia—Docetaxel—ovarian cancer	2.2e-05	0.000312	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—ovarian cancer	2.19e-05	0.000311	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—ovarian cancer	2.19e-05	0.000311	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—ovarian cancer	2.19e-05	0.000311	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—ovarian cancer	2.17e-05	0.000308	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—ovarian cancer	2.16e-05	0.000307	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—ovarian cancer	2.16e-05	0.000307	CcSEcCtD
Methotrexate—Urticaria—Paclitaxel—ovarian cancer	2.16e-05	0.000307	CcSEcCtD
Methotrexate—Hypotension—Docetaxel—ovarian cancer	2.15e-05	0.000306	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—ovarian cancer	2.15e-05	0.000305	CcSEcCtD
Methotrexate—Abdominal pain—Paclitaxel—ovarian cancer	2.15e-05	0.000305	CcSEcCtD
Methotrexate—Body temperature increased—Paclitaxel—ovarian cancer	2.15e-05	0.000305	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—ovarian cancer	2.14e-05	0.000305	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—ovarian cancer	2.13e-05	0.000303	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—ovarian cancer	2.13e-05	0.000302	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—ovarian cancer	2.11e-05	0.000299	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—ovarian cancer	2.1e-05	0.000299	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	2.1e-05	0.000298	CcSEcCtD
Methotrexate—Insomnia—Docetaxel—ovarian cancer	2.08e-05	0.000296	CcSEcCtD
Methotrexate—Paraesthesia—Docetaxel—ovarian cancer	2.07e-05	0.000294	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—ovarian cancer	2.07e-05	0.000294	CcSEcCtD
Methotrexate—Dyspnoea—Docetaxel—ovarian cancer	2.05e-05	0.000292	CcSEcCtD
Methotrexate—Somnolence—Docetaxel—ovarian cancer	2.05e-05	0.000291	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—ovarian cancer	2.04e-05	0.00029	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—ovarian cancer	2.04e-05	0.00029	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—ovarian cancer	2.03e-05	0.000289	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—ovarian cancer	2.03e-05	0.000288	CcSEcCtD
Methotrexate—Dyspepsia—Docetaxel—ovarian cancer	2.03e-05	0.000288	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—ovarian cancer	2.02e-05	0.000288	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—ovarian cancer	2.02e-05	0.000288	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—ovarian cancer	2.01e-05	0.000285	CcSEcCtD
Methotrexate—Decreased appetite—Docetaxel—ovarian cancer	2e-05	0.000285	CcSEcCtD
Methotrexate—Hypersensitivity—Paclitaxel—ovarian cancer	2e-05	0.000285	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—ovarian cancer	2e-05	0.000284	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Docetaxel—ovarian cancer	1.99e-05	0.000283	CcSEcCtD
Methotrexate—Fatigue—Docetaxel—ovarian cancer	1.99e-05	0.000282	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—ovarian cancer	1.98e-05	0.000282	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—ovarian cancer	1.98e-05	0.000282	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—ovarian cancer	1.98e-05	0.000281	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—ovarian cancer	1.97e-05	0.00028	CcSEcCtD
Methotrexate—Pain—Docetaxel—ovarian cancer	1.97e-05	0.00028	CcSEcCtD
Methotrexate—Chills—Epirubicin—ovarian cancer	1.96e-05	0.000279	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—ovarian cancer	1.95e-05	0.000277	CcSEcCtD
Methotrexate—Asthenia—Paclitaxel—ovarian cancer	1.95e-05	0.000277	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—ovarian cancer	1.93e-05	0.000275	CcSEcCtD
Methotrexate—Pruritus—Paclitaxel—ovarian cancer	1.92e-05	0.000273	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—ovarian cancer	1.92e-05	0.000272	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—ovarian cancer	1.91e-05	0.000272	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—ovarian cancer	1.9e-05	0.000271	CcSEcCtD
Methotrexate—Erythema—Epirubicin—ovarian cancer	1.9e-05	0.000271	CcSEcCtD
Methotrexate—Feeling abnormal—Docetaxel—ovarian cancer	1.9e-05	0.00027	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—ovarian cancer	1.89e-05	0.000269	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—ovarian cancer	1.89e-05	0.000268	CcSEcCtD
Methotrexate—Gastrointestinal pain—Docetaxel—ovarian cancer	1.88e-05	0.000268	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—ovarian cancer	1.88e-05	0.000267	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—ovarian cancer	1.86e-05	0.000265	CcSEcCtD
Methotrexate—Diarrhoea—Paclitaxel—ovarian cancer	1.86e-05	0.000264	CcSEcCtD
Methotrexate—Back pain—Epirubicin—ovarian cancer	1.84e-05	0.000262	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—ovarian cancer	1.84e-05	0.000261	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—ovarian cancer	1.83e-05	0.00026	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—ovarian cancer	1.82e-05	0.000259	CcSEcCtD
Methotrexate—Abdominal pain—Docetaxel—ovarian cancer	1.82e-05	0.000259	CcSEcCtD
Methotrexate—Body temperature increased—Docetaxel—ovarian cancer	1.82e-05	0.000259	CcSEcCtD
Methotrexate—Chills—Doxorubicin—ovarian cancer	1.82e-05	0.000258	CcSEcCtD
Methotrexate—Dizziness—Paclitaxel—ovarian cancer	1.8e-05	0.000255	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—ovarian cancer	1.79e-05	0.000255	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—ovarian cancer	1.79e-05	0.000254	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—ovarian cancer	1.77e-05	0.000252	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—ovarian cancer	1.77e-05	0.000251	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—ovarian cancer	1.76e-05	0.00025	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—ovarian cancer	1.76e-05	0.00025	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—ovarian cancer	1.76e-05	0.00025	CcSEcCtD
Methotrexate—Vomiting—Paclitaxel—ovarian cancer	1.73e-05	0.000246	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—ovarian cancer	1.73e-05	0.000245	CcSEcCtD
Methotrexate—Malaise—Epirubicin—ovarian cancer	1.72e-05	0.000244	CcSEcCtD
Methotrexate—Rash—Paclitaxel—ovarian cancer	1.71e-05	0.000244	CcSEcCtD
Methotrexate—Dermatitis—Paclitaxel—ovarian cancer	1.71e-05	0.000243	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—ovarian cancer	1.71e-05	0.000243	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—ovarian cancer	1.7e-05	0.000242	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—ovarian cancer	1.7e-05	0.000242	CcSEcCtD
Methotrexate—Headache—Paclitaxel—ovarian cancer	1.7e-05	0.000242	CcSEcCtD
Methotrexate—Hypersensitivity—Docetaxel—ovarian cancer	1.7e-05	0.000241	CcSEcCtD
Methotrexate—Cough—Epirubicin—ovarian cancer	1.66e-05	0.000236	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—ovarian cancer	1.66e-05	0.000236	CcSEcCtD
Methotrexate—Asthenia—Docetaxel—ovarian cancer	1.65e-05	0.000235	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—ovarian cancer	1.65e-05	0.000234	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—ovarian cancer	1.63e-05	0.000232	CcSEcCtD
Methotrexate—Pruritus—Docetaxel—ovarian cancer	1.63e-05	0.000232	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—ovarian cancer	1.63e-05	0.000231	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—ovarian cancer	1.62e-05	0.00023	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—ovarian cancer	1.62e-05	0.00023	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—ovarian cancer	1.62e-05	0.00023	CcSEcCtD
Methotrexate—Nausea—Paclitaxel—ovarian cancer	1.61e-05	0.000229	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	1.61e-05	0.000229	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—ovarian cancer	1.6e-05	0.000228	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—ovarian cancer	1.59e-05	0.000226	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—ovarian cancer	1.58e-05	0.000225	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—ovarian cancer	1.58e-05	0.000224	CcSEcCtD
Methotrexate—Diarrhoea—Docetaxel—ovarian cancer	1.58e-05	0.000224	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—ovarian cancer	1.57e-05	0.000223	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—ovarian cancer	1.55e-05	0.000221	CcSEcCtD
Methotrexate—Infection—Epirubicin—ovarian cancer	1.54e-05	0.000219	CcSEcCtD
Methotrexate—Cough—Doxorubicin—ovarian cancer	1.54e-05	0.000218	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—ovarian cancer	1.53e-05	0.000217	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—ovarian cancer	1.52e-05	0.000217	CcSEcCtD
Methotrexate—Dizziness—Docetaxel—ovarian cancer	1.52e-05	0.000216	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—ovarian cancer	1.52e-05	0.000216	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—ovarian cancer	1.51e-05	0.000214	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—ovarian cancer	1.5e-05	0.000213	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—ovarian cancer	1.5e-05	0.000213	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—ovarian cancer	1.5e-05	0.000213	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—ovarian cancer	1.5e-05	0.000213	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	1.49e-05	0.000212	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—ovarian cancer	1.48e-05	0.000211	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—ovarian cancer	1.48e-05	0.00021	CcSEcCtD
Methotrexate—Vomiting—Docetaxel—ovarian cancer	1.46e-05	0.000208	CcSEcCtD
Methotrexate—Rash—Docetaxel—ovarian cancer	1.45e-05	0.000206	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—ovarian cancer	1.45e-05	0.000206	CcSEcCtD
Methotrexate—Dermatitis—Docetaxel—ovarian cancer	1.45e-05	0.000206	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—ovarian cancer	1.45e-05	0.000206	CcSEcCtD
Methotrexate—Headache—Docetaxel—ovarian cancer	1.44e-05	0.000205	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—ovarian cancer	1.44e-05	0.000204	CcSEcCtD
Methotrexate—Infection—Doxorubicin—ovarian cancer	1.43e-05	0.000203	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	1.42e-05	0.000201	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—ovarian cancer	1.41e-05	0.0002	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—ovarian cancer	1.41e-05	0.0002	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—ovarian cancer	1.41e-05	0.0002	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—ovarian cancer	1.4e-05	0.000198	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—ovarian cancer	1.4e-05	0.000198	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—ovarian cancer	1.39e-05	0.000197	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—ovarian cancer	1.39e-05	0.000197	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—ovarian cancer	1.38e-05	0.000196	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—ovarian cancer	1.37e-05	0.000195	CcSEcCtD
Methotrexate—Nausea—Docetaxel—ovarian cancer	1.37e-05	0.000194	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—ovarian cancer	1.37e-05	0.000194	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—ovarian cancer	1.35e-05	0.000192	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—ovarian cancer	1.34e-05	0.000191	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—ovarian cancer	1.34e-05	0.000191	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—ovarian cancer	1.34e-05	0.00019	CcSEcCtD
Methotrexate—Pain—Epirubicin—ovarian cancer	1.33e-05	0.000189	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	1.31e-05	0.000186	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—ovarian cancer	1.3e-05	0.000185	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—ovarian cancer	1.29e-05	0.000183	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—ovarian cancer	1.28e-05	0.000182	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—ovarian cancer	1.28e-05	0.000182	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—ovarian cancer	1.28e-05	0.000182	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—ovarian cancer	1.27e-05	0.000181	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—ovarian cancer	1.27e-05	0.00018	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—ovarian cancer	1.25e-05	0.000178	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—ovarian cancer	1.24e-05	0.000176	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—ovarian cancer	1.24e-05	0.000176	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—ovarian cancer	1.23e-05	0.000175	CcSEcCtD
Methotrexate—Pain—Doxorubicin—ovarian cancer	1.23e-05	0.000175	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—ovarian cancer	1.23e-05	0.000175	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—ovarian cancer	1.23e-05	0.000175	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—ovarian cancer	1.18e-05	0.000168	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—ovarian cancer	1.18e-05	0.000167	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—ovarian cancer	1.14e-05	0.000163	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—ovarian cancer	1.14e-05	0.000162	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—ovarian cancer	1.14e-05	0.000162	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—ovarian cancer	1.14e-05	0.000162	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—ovarian cancer	1.11e-05	0.000158	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—ovarian cancer	1.1e-05	0.000156	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—ovarian cancer	1.06e-05	0.000151	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—ovarian cancer	1.06e-05	0.000151	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—ovarian cancer	1.03e-05	0.000147	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—ovarian cancer	1.03e-05	0.000146	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—ovarian cancer	1.02e-05	0.000145	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—ovarian cancer	9.88e-06	0.00014	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—ovarian cancer	9.84e-06	0.00014	CcSEcCtD
Methotrexate—Rash—Epirubicin—ovarian cancer	9.8e-06	0.000139	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—ovarian cancer	9.79e-06	0.000139	CcSEcCtD
Methotrexate—Headache—Epirubicin—ovarian cancer	9.74e-06	0.000138	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—ovarian cancer	9.51e-06	0.000135	CcSEcCtD
Methotrexate—Nausea—Epirubicin—ovarian cancer	9.23e-06	0.000131	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—ovarian cancer	9.14e-06	0.00013	CcSEcCtD
Methotrexate—Rash—Doxorubicin—ovarian cancer	9.07e-06	0.000129	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—ovarian cancer	9.06e-06	0.000129	CcSEcCtD
Methotrexate—Headache—Doxorubicin—ovarian cancer	9.01e-06	0.000128	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—ovarian cancer	8.54e-06	0.000121	CcSEcCtD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.63e-06	0.000112	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CAV1—ovarian cancer	3.62e-06	0.000112	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP1B1—ovarian cancer	3.61e-06	0.000111	CbGpPWpGaD
Methotrexate—PGD—Disease—PIK3CA—ovarian cancer	3.6e-06	0.000111	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—MAPK3—ovarian cancer	3.59e-06	0.000111	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SLC2A1—ovarian cancer	3.58e-06	0.00011	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1B—ovarian cancer	3.57e-06	0.00011	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPP2R1A—ovarian cancer	3.56e-06	0.00011	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.54e-06	0.000109	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERBB2—ovarian cancer	3.51e-06	0.000108	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.5e-06	0.000108	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IL6—ovarian cancer	3.49e-06	0.000108	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—FASN—ovarian cancer	3.49e-06	0.000108	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—ovarian cancer	3.47e-06	0.000107	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CB—ovarian cancer	3.46e-06	0.000107	CbGpPWpGaD
Methotrexate—DHFR—Disease—MTOR—ovarian cancer	3.46e-06	0.000107	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—ovarian cancer	3.46e-06	0.000107	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—ovarian cancer	3.46e-06	0.000107	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—ovarian cancer	3.45e-06	0.000107	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPP1CC—ovarian cancer	3.45e-06	0.000106	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CG—ovarian cancer	3.45e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—BRIP1—ovarian cancer	3.45e-06	0.000106	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.44e-06	0.000106	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP1B1—ovarian cancer	3.43e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC5A5—ovarian cancer	3.43e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—MAPK1—ovarian cancer	3.41e-06	0.000105	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—ovarian cancer	3.37e-06	0.000104	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTEN—ovarian cancer	3.37e-06	0.000104	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—ovarian cancer	3.33e-06	0.000103	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	3.33e-06	0.000103	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CD—ovarian cancer	3.33e-06	0.000103	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CAV1—ovarian cancer	3.33e-06	0.000103	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC2A1—ovarian cancer	3.31e-06	0.000102	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CG—ovarian cancer	3.3e-06	0.000102	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ABCB1—ovarian cancer	3.3e-06	0.000102	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—ovarian cancer	3.3e-06	0.000102	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTEN—ovarian cancer	3.29e-06	0.000101	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.28e-06	0.000101	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CB—ovarian cancer	3.26e-06	0.000101	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1B—ovarian cancer	3.25e-06	0.0001	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—ovarian cancer	3.24e-06	0.0001	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TYMS—ovarian cancer	3.24e-06	0.0001	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—ovarian cancer	3.22e-06	9.94e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—ovarian cancer	3.22e-06	9.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPP2R1A—ovarian cancer	3.2e-06	9.87e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—ovarian cancer	3.19e-06	9.83e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CB—ovarian cancer	3.19e-06	9.83e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.18e-06	9.82e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.18e-06	9.8e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1B1—ovarian cancer	3.17e-06	9.79e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CAV1—ovarian cancer	3.15e-06	9.71e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	3.15e-06	9.71e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.1e-06	9.56e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—ovarian cancer	3.07e-06	9.47e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPP2R1A—ovarian cancer	3.04e-06	9.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TERT—ovarian cancer	3.04e-06	9.36e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CD—ovarian cancer	3.03e-06	9.35e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CG—ovarian cancer	3.03e-06	9.34e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.03e-06	9.33e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—ovarian cancer	3.02e-06	9.3e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.01e-06	9.3e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—ovarian cancer	3.01e-06	9.29e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—ovarian cancer	3e-06	9.27e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CAV1—ovarian cancer	3e-06	9.26e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	3e-06	9.24e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTEN—ovarian cancer	2.99e-06	9.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ABCB1—ovarian cancer	2.97e-06	9.16e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—ovarian cancer	2.96e-06	9.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.95e-06	9.1e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.95e-06	9.1e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—ovarian cancer	2.94e-06	9.07e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—ovarian cancer	2.94e-06	9.07e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—ovarian cancer	2.93e-06	9.05e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TYMS—ovarian cancer	2.92e-06	9e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CD—ovarian cancer	2.9e-06	8.95e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CB—ovarian cancer	2.9e-06	8.94e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MAPK3—ovarian cancer	2.88e-06	8.87e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CG—ovarian cancer	2.87e-06	8.85e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.87e-06	8.84e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.87e-06	8.84e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—ovarian cancer	2.86e-06	8.83e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ABCB1—ovarian cancer	2.82e-06	8.71e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTEN—ovarian cancer	2.82e-06	8.7e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPP2R1A—ovarian cancer	2.82e-06	8.68e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MAPK3—ovarian cancer	2.81e-06	8.67e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CAV1—ovarian cancer	2.81e-06	8.66e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—ovarian cancer	2.8e-06	8.63e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.79e-06	8.59e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TYMS—ovarian cancer	2.77e-06	8.55e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—ovarian cancer	2.75e-06	8.5e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—ovarian cancer	2.74e-06	8.45e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MAPK1—ovarian cancer	2.74e-06	8.44e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—ovarian cancer	2.74e-06	8.44e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CG—ovarian cancer	2.73e-06	8.43e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—ovarian cancer	2.73e-06	8.43e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—ovarian cancer	2.69e-06	8.31e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—ovarian cancer	2.68e-06	8.25e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MAPK1—ovarian cancer	2.67e-06	8.25e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—ovarian cancer	2.67e-06	8.25e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—ovarian cancer	2.67e-06	8.23e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CD—ovarian cancer	2.66e-06	8.21e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6ST—ovarian cancer	2.66e-06	8.21e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CB—ovarian cancer	2.64e-06	8.15e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—YAP1—ovarian cancer	2.64e-06	8.14e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—ovarian cancer	2.61e-06	8.06e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CAV1—ovarian cancer	2.61e-06	8.06e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.61e-06	8.05e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	2.6e-06	8.02e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—ovarian cancer	2.59e-06	7.98e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TYMS—ovarian cancer	2.57e-06	7.92e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.56e-06	7.89e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—ovarian cancer	2.56e-06	7.89e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK3—ovarian cancer	2.56e-06	7.89e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—ovarian cancer	2.53e-06	7.8e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—ovarian cancer	2.53e-06	7.79e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—ovarian cancer	2.52e-06	7.78e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—ovarian cancer	2.51e-06	7.73e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.5e-06	7.7e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—ovarian cancer	2.49e-06	7.67e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.48e-06	7.64e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—ovarian cancer	2.46e-06	7.6e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK1—ovarian cancer	2.43e-06	7.5e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—ovarian cancer	2.43e-06	7.5e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—ovarian cancer	2.42e-06	7.46e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—ovarian cancer	2.4e-06	7.41e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—ovarian cancer	2.38e-06	7.34e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—ovarian cancer	2.38e-06	7.33e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CAV1—ovarian cancer	2.35e-06	7.25e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—ovarian cancer	2.32e-06	7.16e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—ovarian cancer	2.32e-06	7.16e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—YAP1—ovarian cancer	2.31e-06	7.13e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—ovarian cancer	2.3e-06	7.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.3e-06	7.08e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—ovarian cancer	2.28e-06	7.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—ovarian cancer	2.25e-06	6.93e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.25e-06	6.93e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CAV1—ovarian cancer	2.23e-06	6.89e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—ovarian cancer	2.2e-06	6.78e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—ovarian cancer	2.2e-06	6.78e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—ovarian cancer	2.19e-06	6.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—FASN—ovarian cancer	2.15e-06	6.63e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—ovarian cancer	2.15e-06	6.62e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—ovarian cancer	2.14e-06	6.61e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.13e-06	6.58e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	2.12e-06	6.55e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC5A5—ovarian cancer	2.12e-06	6.53e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—ovarian cancer	2.11e-06	6.51e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—ovarian cancer	2.1e-06	6.49e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—ovarian cancer	2.09e-06	6.46e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—ovarian cancer	2.09e-06	6.45e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.09e-06	6.45e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAV1—ovarian cancer	2.07e-06	6.38e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—ovarian cancer	2.05e-06	6.34e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A1—ovarian cancer	2.04e-06	6.3e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—ovarian cancer	2.04e-06	6.28e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—ovarian cancer	2.02e-06	6.23e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—ovarian cancer	2.01e-06	6.19e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2e-06	6.17e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—ovarian cancer	1.99e-06	6.14e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—ovarian cancer	1.99e-06	6.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—ovarian cancer	1.96e-06	6.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—ovarian cancer	1.96e-06	6.04e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1B1—ovarian cancer	1.96e-06	6.04e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—ovarian cancer	1.95e-06	6.02e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—ovarian cancer	1.94e-06	5.99e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—ovarian cancer	1.94e-06	5.99e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—ovarian cancer	1.9e-06	5.85e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—ovarian cancer	1.88e-06	5.81e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—FASN—ovarian cancer	1.88e-06	5.81e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—ovarian cancer	1.88e-06	5.81e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—ovarian cancer	1.87e-06	5.77e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.85e-06	5.72e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—ovarian cancer	1.84e-06	5.67e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—ovarian cancer	1.82e-06	5.63e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—ovarian cancer	1.81e-06	5.58e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.79e-06	5.52e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—ovarian cancer	1.79e-06	5.52e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—ovarian cancer	1.77e-06	5.45e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPP2R1A—ovarian cancer	1.74e-06	5.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—ovarian cancer	1.74e-06	5.36e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.73e-06	5.33e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—ovarian cancer	1.72e-06	5.32e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.72e-06	5.29e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—ovarian cancer	1.72e-06	5.29e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—ovarian cancer	1.69e-06	5.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—ovarian cancer	1.69e-06	5.22e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—ovarian cancer	1.66e-06	5.11e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—ovarian cancer	1.64e-06	5.06e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—ovarian cancer	1.62e-06	5.01e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK3—ovarian cancer	1.62e-06	5.01e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—ovarian cancer	1.61e-06	4.98e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—ovarian cancer	1.61e-06	4.97e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—ovarian cancer	1.59e-06	4.9e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMS—ovarian cancer	1.58e-06	4.89e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—ovarian cancer	1.58e-06	4.86e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—ovarian cancer	1.56e-06	4.81e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK1—ovarian cancer	1.54e-06	4.76e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—ovarian cancer	1.54e-06	4.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.52e-06	4.7e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—ovarian cancer	1.51e-06	4.67e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—ovarian cancer	1.51e-06	4.66e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—ovarian cancer	1.46e-06	4.5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK3—ovarian cancer	1.45e-06	4.46e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—ovarian cancer	1.44e-06	4.45e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—ovarian cancer	1.44e-06	4.45e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—ovarian cancer	1.42e-06	4.37e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—ovarian cancer	1.41e-06	4.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—ovarian cancer	1.41e-06	4.34e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMS—ovarian cancer	1.39e-06	4.28e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK1—ovarian cancer	1.38e-06	4.25e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—ovarian cancer	1.38e-06	4.25e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—ovarian cancer	1.35e-06	4.16e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—ovarian cancer	1.34e-06	4.13e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—ovarian cancer	1.32e-06	4.06e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—ovarian cancer	1.3e-06	4.01e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—ovarian cancer	1.3e-06	4e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—ovarian cancer	1.28e-06	3.94e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAV1—ovarian cancer	1.28e-06	3.94e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—ovarian cancer	1.26e-06	3.89e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—ovarian cancer	1.25e-06	3.85e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—ovarian cancer	1.24e-06	3.82e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.22e-06	3.76e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—ovarian cancer	1.19e-06	3.68e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—ovarian cancer	1.16e-06	3.59e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—ovarian cancer	1.16e-06	3.57e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAV1—ovarian cancer	1.12e-06	3.45e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—ovarian cancer	1.11e-06	3.43e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—ovarian cancer	1.11e-06	3.41e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—ovarian cancer	1.09e-06	3.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—ovarian cancer	1.06e-06	3.26e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—ovarian cancer	1.04e-06	3.22e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—ovarian cancer	1.02e-06	3.15e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.02e-06	3.14e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—ovarian cancer	1e-06	3.09e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—ovarian cancer	9.76e-07	3.01e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	9.51e-07	2.93e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—ovarian cancer	9.08e-07	2.8e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—ovarian cancer	8.96e-07	2.76e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—ovarian cancer	8.91e-07	2.75e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—ovarian cancer	8.8e-07	2.72e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—ovarian cancer	8.17e-07	2.52e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—ovarian cancer	7.81e-07	2.41e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—ovarian cancer	7.77e-07	2.4e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—ovarian cancer	7.7e-07	2.38e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—ovarian cancer	7.19e-07	2.22e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—ovarian cancer	6.75e-07	2.08e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—ovarian cancer	5.43e-07	1.68e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—ovarian cancer	4.76e-07	1.47e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—ovarian cancer	4.44e-07	1.37e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—ovarian cancer	3.89e-07	1.2e-05	CbGpPWpGaD
